BioSpace News Archive

July 1, 2020 10:00 UTC IRVING, Texas--( BUSINESS WIRE )-- A study facilitated by Vizient, Inc. and recently published in the Journal of American Medical Association Internal Medicine yielded new insights about patients with presumed penicillin allergies. The study, led by researchers at Massachusetts General Hospital, found that physicians unnecessarily prescribe inferior antibiotic alternatives to patients with documented penicillin allergies. Because 90% of documented penicill

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that the Investigational New Drug Application for MN-166 for prevention of Acute Respiratory Distress Syndrome has been accepted and is now open with the U.S. Food and Drug Administration.

Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug application for a Phase II clinical trial of Antroquinonol on COVID-19 patients in USA.

Anavex Life Sciences Corp. announced that the first patient was dosed in the EXCELLENCE Phase 2/3 ANAVEX®2-73-RS-003 clinical trial for the treatment of Rett syndrome with ANAVEX®2-73.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced the launch of a new patient home collection kit for the GeneSight® Psychotropic test.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced a financing agreement with Oberland Capital and provided preliminary, estimated revenue for the second quarter ended June 30, 2020.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced the appointment of Kimberly Blackwell, M.D. to its Board of Directors.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Gilead Raday, RedHill’s Chief Operating Officer, will present the Company’s ongoing Phase 2/3 development programs with opaganib 1 and RHB-107 2 for COVID-19 at the Sachs Digital Novel Coronavirus Investment Forum, taking place July 7-9, 2020.

KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020

Therapix Biosciences Ltd. (Nasdaq: TRPX) (the “Company” or “Therapix”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court. Notice of Delisting On June 30, 2020 , Therapix Biosci